In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gyrus and ACMI--A Great Marriage, But What's Next?

Executive Summary

The recent acquisition of ACMI by Gyrus boosts both companies considerably and creates a powerful competitor in urology, gynecology, and general surgery. But having created critical mass, have they also attracted the attention of much larger companies--threatening both the comfortable niches they occupy and their independence?

You may also be interested in...



Stanmore: Creating a Specialty Orthopedics Company

Long a pioneer in prosthetics, one of orthopedics' forgotten spaces, Stanmore Implants Worldwide, has a new investor group who hope to transform this once academic supplier into a thriving orthopedics player by focusing on specialty niches that the Ortho giants have largely ignored.

Scratch-Free Skin Resurfacing

In the red-hot skin cosmetic surgery market, Reliant Technologies and Rhytec aim for the market gap between ablative laser skin resurfacing and gentler, but less effective technologies. Their devices match the resurfacing and regenerative power of CO2 lasers, but with less tissue destruction and therefore shorter procedures and faster recoveries.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel